Exploring Vaccine Efficacy and Safety for MS Patients on Immunosuppressant Treatment in Light of the COVID-19 Pandemic

Multiple sclerosis (MS) is a chronic neurodegenerative autoimmune disorder affecting approximately 2.8 million people worldwide. Despite decades of research to understand the molecular mechanisms of MS pathology, little is known about why the neurodegeneration caused by this illness occurs. For this reason, current treatments for MS target two broader aspects of the disease: relapse management and prevention via disease-modifying therapies. These treatments often involve immunosuppressive mechanisms, creating vulnerability to infectious diseases that became particularly concerning during the COVID-19 pandemic. This literature review examines the safety and efficacy of vaccination for MS patients on immunosuppressant therapies, highlighting the novel mRNA vaccines developed for COVID-19 and potential interactions between these vaccines and MS treatments. While mRNA vaccination is generally safe and recommended for MS patients, immunosuppressive therapies can reduce the effectiveness of vaccination, necessitating individualized vaccination timing and improved patient-provider communication. Future research should focus on improving understanding of MS pathology on a molecular level, creating personalized treatment plans, and prioritizing clear communication with patients.